Seeking Alpha


Send Message
View as an RSS Feed
View richwolol's Comments BY TICKER:
Latest  |  Highest rated
  • Exide Technologies (XIDE -49%) resumes trading after a brief halt and plunges; the move is attributed to news suggesting the company has hired Lazard and Akin after traditional refinancing efforts stalled. Also, a Los Angeles Times story out last night discussed potential arsenic concerns at its L.A.-area battery recycling factory. [View news story]
    The stock is under siege by shorters who wish to pummel it's vaue into the ground.
    Apr 4 04:19 PM | Likes Like |Link to Comment
  • Biogen Idec (BIIB +2.8%) on a mixed Q4 report, missing on its bottom line but slightly beating on revenue. Net earnings actually fell 2.7% Y/Y, due largely to the company's preparations to launch its new multiple sclerosis drug BG-12, which masked revenue growth from its existing MS treatment. The company also boosted its FY13 revenue growth expectations to 10%. Analysts are looking for a 9% rise to $5.98B. [View news story]
    The writer is obviously biased. I do not think a 10% rise in revenue is a "slight" one. Get a job if you can't figure things out correctly and accurately.
    Jan 28 04:21 PM | Likes Like |Link to Comment
  • Pharma: Don't Count Elan Out [View article]
    KM has been sucking out profits from this company for as long as he has been there. One comes away realizing Ireland markets are as bad as the mess we have on Wall Street.
    Jul 24 08:58 AM | Likes Like |Link to Comment
  • The U.S.: Stuck In The Slow Lane For How Long? [View article]
    Unfortunately for all US investors, partisan politicians on the right are negatively propogandizing all that is economic news. Doom and gloom forecasters are abound now that Wall street and Obama are on the outs. They want so badly to defeat the president that they do not care if all ordinary investors (those who do not make hedge bets or short stocks) lose a lot of their investment capital between now and elction day. Conversely, if Romney is elected, shorting and hedging of investments will end. The negative propaganda will abate and the market will be allowed to find it's proper level.
    May 12 10:08 AM | 1 Like Like |Link to Comment
  • Elan (ELN) CEO Kelly Martin, who planned to step down May 1, will stay on the job until data is published from late-stage clinical trials of an experimental Alzheimer’s drug. The results on the drug are “potentially of transformational significance," says Chairman Robert Ingram in a statement released this morning.  [View news story]
    It's time for this loser to leave. He has been an anchor for Elan for as long as he has been there.....Perhaps it's time for the Bd of Directors to remove him since he will not leave.....
    Mar 1 11:55 AM | Likes Like |Link to Comment
  • 10 Reasons to Buy Teva Pharmaceuticals [View article]
    Copaxone has long been the cash cow for Teva. Besides coming of patent soon, the word is out that Copaxone is at or near the bottom of efficy for all drugs designed to reduce exaerbation rates.....Tysabri is in high 70% range while Copaxone is only in the high 20s percent range.................The author should know this.......
    Aug 11 01:34 PM | Likes Like |Link to Comment
  • 10 Reasons to Buy Teva Pharmaceuticals [View article]
    Teva makes very little profits from their generics. Heretofore they were making an inordinately high rate of profit on their MS drug Copaxone. Copaxone is under a lot of pressure since there are 4 or 5 others that do a better job in preventing exacerbations. Besides, who wants to take Copaxone and suffer from a permanent flu like side effect.....The truth was a long time coming but eventually it did.....
    Jun 6 11:48 AM | 1 Like Like |Link to Comment
  • 10 Good Looking Stocks in This Nervous Market [View article]
    A good artticle. Not mentioned is the alliance between short sellers and the shills who write here on the internet on their behalf.........
    Jun 4 11:07 AM | 1 Like Like |Link to Comment
  • Microsoft: In-Depth Analysis for the December 2010 Quarter [View article]
    It's too bad the investors are more impressed with the marketing propogandists at Apple rather then hard data facts presented by the author of the above above.
    Jan 30 10:07 AM | 1 Like Like |Link to Comment
  • S&P 500: Will May's Panic Continue Into June? [View article]
    I do not trust anyones opinion these days. He is no doubt short.....
    Jun 7 03:46 PM | Likes Like |Link to Comment
  • Looking for the Biotech Breakout [View article]
    How can you report the pending breakout of Biotechs, including BIIB but not ELN. The drug Tysabri is co-owned (50%) owned by each company
    Jan 19 09:05 AM | 1 Like Like |Link to Comment
  • Time to Buy Elan? [View article]
    It is refreshing to read an accurate historical doocument about Elan and their trials and tribulations. Also refreshing to hear the author tell what I an many others know: Tysabri is the most effective drug to combat the ravages of MS. What could have been emphasized and was not is that when taken as per the label requirements the chances of contracting PML are close to Nil. In these latest two instances, I beleive it would be extremely helpful if Elan hired a few well seasoned investigators to examine the medical history. Since both of these PML sufferers are from Europe where socialized medicine is practiced, it should be quite simple to determine what drugs these persons imbibed. There must be rocords of whatever drugs have been dispensed. I have already heard that patient number one had a history of taking Azathioprine, one of the drugs forbidden to have taken or perhaps still taking while having Tysabri infused. With patient number 2, I wonder what has taken so long to get a history of what drugs he was imbibing. Making light of their findings will make prescribing neuros more careful on who they put onto Tysabri. Elan needs the services of a old retired NYPD detective to work with the boatload of scientists they already have. r
    Aug 4 09:04 AM | Likes Like |Link to Comment
  • 21 Airline Stocks to Keep You Flying High This Summer [View article]
    The writer of the article has an obvious bias (at least he admits to being long on JBLU). He failed to even mention Airtran (AAI) that has newer more economical airplanes and a much lower PE ratio. They also move one person one mile at a lower cost then any airline operating in the US. If anyone is poised to leap out if and when the climate changes, it will be Air Tran at a much higher rate then JBlU. Granted JBLU, gets a lot of hype, good markeeting and is in a good position, but no match compared to Air Tran.
    May 25 01:19 PM | Likes Like |Link to Comment